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Abstract
Purpose—We compared the frequency and sequence of breast imaging and biopsy use for the 
diagnostic and preoperative workup of breast cancer according to breast MRI use among older 
women.
Methods—Using SEER-Medicare data from 2004–2010, we identified women with and without 
breast MRI as part of their diagnostic and preoperative breast cancer workup and measured the 
number and sequence of breast imaging and biopsy events per woman.
Results—10,766 (20%) women had an MRI in the diagnostic/preoperative period, 32,178 (60%) 
had mammogram and US, and 10,669 (20%) had mammography alone. MRI use increased across 
study years, tripling from 2005 to 2009 (9% to 29%). Women with MRI had higher rates of breast 
imaging and biopsy compared to those with mammogram and US or those with mammography 
alone (5.8 v 4.1 v 2.8; respectively). There were 4,254 unique sequences of breast events; the 
dominant patterns for women with MRI were an MRI occurring at the end of the care pathway. 
Among women receiving an MRI post-diagnosis, 26% had a subsequent biopsy compared to 51% 
receiving a subsequent biopsy in the sub-group without MRI.
Conclusions—Older women who receive breast MRI undergo additional breast imaging and 
biopsy events. There is much variability in the diagnostic/preoperative work-up in older women, 
demonstrating the opportunity to increase standardization to optimize care for all women.
Keywords
magnetic resonance imaging (MRI); breast cancer; preoperative; utilization
BACKGROUND
Diagnosis and preoperative workup for women with breast cancer can include evaluation 
using several imaging modalities and breast biopsy. Breast magnetic resonance imaging 
(MRI) is increasingly used as an adjunct imaging modality to determine extent of disease 
and for preoperative planning. 1–5 The potential benefits of preoperative MRI – such as 
lower reoperation rates, lower likelihood of recurrence, and improved mortality – have not 
been substantiated in the literature. 6, 7 Higher breast biopsy rates have been associated with 
preoperative MRI use 8, 9 and greater overall utilization of breast-related services has been 
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hypothesized in relation to breast MRI for women newly diagnosed with breast cancer. 10 
With approximately 25% of older women and 58% of younger women with breast cancer 
receiving a preoperative MRI, 11, 12 it is important to fill gaps in the evidence-base for 
limitations and benefits of preoperative MRI.
Breast MRI has greater sensitivity than mammography and ultrasound; 13, 14 thus, detects 
additional lesions, both cancerous and non-cancerous. 9, 15, 16 Detection of additional lesions 
may lead to further workup before surgical treatment. Increased use of breast services results 
in additional costs, procedures,, and potentially, a delay in treatment. There have been no 
reports in the literature on differences in number or type of imaging and biopsies used with 
pre- and perioperative breast MRI for women with breast cancer. 12 Several studies, 
however, have shown that use of preoperative breast MRI is significantly associated with 1–
3 week delays in treatment.13, 17 While a delay in treatment may not impact survival, it can 
result in psychological burden for women. 13, 18, 19 Comparing mammography, ultrasound 
(US), and biopsy use during the diagnostic and preoperative workup in relation to 
preoperative MRI use for women with breast cancer will help elucidate whether there are 
additional burdens of care that should be considered in weighing the tradeoffs of MRI use.
We examined population-based patterns of breast care for older women with breast cancer 
who did and did not receive breast MRI in the diagnostic and preoperative periods. Using 
SEER-Medicare data, we estimated: 1) frequency of breast imaging and breast biopsy by 
receipt of advanced imaging, 2) imaging and biopsy use sequencing, and 3) time from the 
first breast imaging use to surgical treatment.
METHODS
Data and Study Population
SEER-Medicare data (2004–2010) were used for this study. 20, 21 The study cohort included 
women aged 66 years or older at the time of an incident breast cancer diagnosis in 2005–
2009 with no prior breast cancer (N=71,193) and concurrent enrollment in Medicare parts A 
and B. Women were excluded if: they lacked a pathologic breast cancer diagnosis(i.e. 
without a histologic confirmation), were diagnosed in a nursing home, did not receive 
cancer-directed surgery, did not have at least one breast imaging claim (mammogram, US, or 
MRI) performed during the diagnostic/preoperative window (defined below; 2,332 women 
had surgery on or within days of diagnosis). Lastly, we excluded women who did not receive 
surgery, as a first course of treatment within six months of the diagnosis date (N=7,496), 
resulting in a final cohort of 53,653 women. The study was approved by the Committee for 
Protection of Human Subjects.
Main Variable Definitions
The diagnostic/preoperative window was defined as the period between the initial breast 
imaging or biopsy within 60 days prior to diagnosis and the primary surgical treatment. We 
refer to any breast imaging (both screening and diagnostic) or breast biopsy (including the 
biopsy associated with the initial cancer diagnosis (DXBX)), occurring during the 
diagnostic/preoperative window as a breast event. We assumed that multiple images 
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occurring on the same-day occurred in the following order: 1) mammogram, 2) US, and 3) 
MRI (i.e. MAM|US, MAM|MRI, US|MRI or MAM|US|MRI). If a biopsy was performed on 
the same day as imaging, we considered the imaging to occur first. For each woman, an 
imaging hierarchy was applied to describe the most advanced imaging modality in the 
diagnostic/preoperative window as follows: 1) MRI, 2) mammogram and US, and 3) 
mammogram alone. We classified women as receiving MRI if receipt of MRI occurred 
anytime during the diagnostic/preoperative window.
Patient and Tumor Characteristics
Women’s characteristics included a) age at diagnosis, b) race, collapsed to white, black and 
other due to small cell sizes, c) rural or urban residence, d) SEER registry, e) ZIP-level 
median household income, f) diagnosis year, g) breast cancer characteristics including: 
stage, histology, grade, nodal status, hormone receptor status, and size. We categorized 
primary treatment into mastectomy, breast conserving surgery with radiation or breast 
conserving surgery without radiation. We measured comorbidities as defined by the 
Klabunde adaptation of the Charlson Index. 22
Analysis
Frequency distributions of patient and tumor characteristics by the most advanced imaging 
modality used are presented. Unadjusted per capita breast event rates for the total number of 
breast events per woman, the number of each imaging breast event type per woman and the 
number of biopsy breast events per woman were examined by most advanced imaging 
modality used. For each group, the mean predicted per capita breast event rates and 95% 
confidence intervals (CI) were estimated using a Poisson model with standardization via 
predicted margins to adjust for all available patient and tumor characteristics.
Each woman’s breast event sequence was chronologically ordered, noting her diagnostic 
biopsy. To compare the utilization of diagnostic and preoperative workup with and without 
MRI, women were grouped by number of breast events and we examined the five most 
common breast event sequences.
The women were classified into two imaging groups, with and without MRI. After 
identifying the first occurrence of an MRI or mammogram/US in each imaging group, we 
analyzed the sequence of breast events following the first imaging event. We dichotomized 
women according to whether a biopsy occurred after the first imaging event. We report the 
proportion of women with a subsequent biopsy following an image by image group. 
Analyses were conducted in SAS (SAS 9.4 System Options: Reference, Second Edition. 
Cary, NC: SAS Institute Inc.; 2011) and Stata/SE 12.1 (StataCorp. 2011. Stata 12 Base 
Reference Manual. College Station, TX: Stata Press).
RESULTS
Of the 53,653 women, 10,766 (20%) had an MRI, the majority had mammogram and US 
(32,178; 60%), and 10,669 (20%) had mammography alone. (Table 1) Two percent of 
women (729/32,178) had only US and were assigned to the mammogram and US group. 
MRI use tripled from 2005 to 2009 (9% to 29%). (Table 1) The overall median time from 
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initial breast event to surgical treatment was 46 days (IQR: 30–66) and by imaging: MRI, 54 
days (IQR: 37–76); US, 43 days (IQR: 28–63); Mammogram, 47 days (IQR: 31–67).
On average, women in the MRI group had 5.8 breast events, while mammogram and US 
group had 4.1 and mammography alone, 2.8. The MRI group had a small increase in 
biopsies compared to the US and mammography alone groups (1.4 v. 1.2 and 1.2, 
respectively), but most of the additional breast events were imaging events. (Table 2) 
Adjusting the per capita breast event rate for woman and tumor characteristics, we found 
similar patterns to the unadjusted estimates. (Table 3) The per capita breast event rate for the 
mammogram and US group was slightly greater than the mammography alone group, which 
appears to account for the US exam itself.
There were 4,254 different breast event sequences among the women in the study cohort 
(2,692 among MRI users, 1,562 without MRI). Figure 1 depicts the 5 most common 
sequences by number of breast events for women with MRI (N=10,766) and without MRI 
(N=42,887). Each sequence is displayed by combination of events on different claim dates 
and events occurring on the same day (see Legend, Figure 1). Sixty-five percent of women 
(N=27,905) with no MRI had 3 (34%) or 4 (31%) breast events with the most common 
sequence being a mammogram/US on the same day followed by a diagnostic biopsy 
(N=6,897; 3 breast events). Among women in the MRI group, an MRI occurred post-
diagnosis for 9,196 women (85%) with 7,146 (66%) having 4 (20%), 5 (26%), or 6 (20%) 
breast events. The most common breast event sequence was a mammogram/US on the same 
day, followed by a diagnostic biopsy and concluding with an MRI (N=714; 4 breast events). 
Among the subgroup of women who had any breast imaging post-diagnosis, a biopsy 
followed the imaging event for 51% of women without an MRI compared to 26% of women 
with an MRI (p<0.001).
DISCUSSION
Evidence of increasing overall imaging rates in the era of advanced imaging11–13, 23 has led 
to concerns about the extent of imaging utilization in many clinical settings, including breast 
cancer diagnosis and workup. 24 Breslin et al. 12 reported a higher number of traditional and 
advanced imaging tests among women with preoperative MRI, which increased over time 
(2005–2008). In their large study population (N=52,202) of commercially-insured younger 
women (<65 years), they concluded that advanced imaging was additive rather than 
replacing traditional imaging in the diagnostic workup of breast cancer. Our study presents 
similar findings for the Medicare population noting up to 2.5 times compared to 
mammography alone and 1.5 times for mammography/US among women with breast MRI.
In a prospective multi-institutional study of 969 women with preoperative MRI, Lehman et 
al. reported that 13% underwent biopsy based on the MRI 15, while another study (N=141) 
found that 29% of preoperative evaluations led to biopsy. 25 In the present study, we found a 
modestly higher rate of biopsy among women with and without MRI in the diagnostic and 
preoperative period. By mapping the sequence of breast events in our study population, we 
found that MRI is usually among the last breast events prior to primary surgical treatment, 
so relatively few biopsies are likely to occur because of MRI among older women. 
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Furthermore, when we examined the subgroup of women with an imaging event post-
diagnosis, we found a significantly smaller percent of the women had biopsies following an 
MRI, compared to women whose biopsy followed a mammogram and ultrasound. These 
findings are important when evaluating the potential risks and benefits of preoperative MRI. 
If relatively few additional biopsies result from MRI, then that may be a less likely potential 
harm, yet may afford the benefit of better determining extent of disease prior to the primary 
surgery.
Similar to other studies reporting longer periods between imaging and treatment 13, 18 we 
found the MRI group to be delayed by a week compared to the other groups. Although these 
delays are not likely to affect recurrence or mortality, women need this evidence to help 
them weigh any potential benefit against risks that may be important to them, such as 
anxiety due to longer time between initial imaging and their definitive treatment.
Our examination of entire care episodes associated with breast cancer diagnosis and initial 
surgical management in a large nationally representative sample is unique, but we note 
limitations, including age restriction to 66+, generalizability to fee-for-service delivery 
systems only, inability to account for women’s preferences, or clinical rationale, such as 
monitoring neoadjuvent chemotherapy. Also, breast density is not available in SEER-
Medicare data, therefore we were not able adjust for breast density in the model. Although 
we examined MRI use by year, there may be heterogeneity of patterns of care within 
episodes. These limitations were considered when interpreting our results.
Because studies in both older and younger women with breast cancer have shown an 
increased use of breast MRI during the preoperative period – with between 22% and 68% 
receiving MRI, 2628 generating evidence to weigh the factors likely to be involved in the 
tradeoffs of benefit and limitations, is important.
Our study demonstrates that older women receiving diagnostic/preoperative MRI undergo 
more breast events than those without MRI and is most often performed as the final test. Our 
finding of 4,000 different breast event combinations indicates there is much variability in the 
diagnostic/preoperative work-up in older women, demonstrating the opportunity to increase 
standardization as a means to optimize clinical care.
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Figure 1. 
The number of women and sequence frequency for the five most common breast event 
sequences for each number of breast events during the diagnostic/preoperative window, by 
preoperative MRI groups, among women (N=53,653) who were enrolled in Medicare 
(2004–2010) with a diagnosis of breast cancer (2005–2009)
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Table 3
Adjusted1 mean predicted per capita breast event rate2 and 95% CIs3 by most advanced imaging modality, 
among women (N=53,653) who were enrolled in Medicare (2004–2010) with a diagnosis of breast cancer 
(2005–2009) during the diagnostic/preoperative window
Most Advanced Imaging
Modality
Summary of Mean Predicted Per Capita Breast Event Rates
Total Imaging Biopsy
Mean 95% CI Mean 95% CI Mean 95% CI
MRI 5.75 (5.74, 5.77) 4.34 (4.33, 4.35) 1.41 (1.41, 1.42)
Mammogram and US 4.09 (4.09, 4.10) 2.87 (2.87, 2.88) 1.22 (1.22, 1.22)
Mammogram only 2.84 (2.83, 2.85) 1.61 (1.60, 1.62) 1.23 (1.22, 1.23)
Total 4.27 (4.27, 4.29) 3.02 (3.01, 3.03) 1.26 (1.26, 1.27)
1
Poisson models adjusted for patient and tumor characteristics
2
Per Capita breast event rate = Number of (MRI, Ultrasound, Mammogram, Biopsy) per woman
3CIs = Confidence Intervals
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